Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biogen to License Alzheimer Candidate from Bristol-Myers
by Zacks Equity Research
Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
MiMedx Group (MDXG) Catches Eye: Stock Jumps 8.5% in Session
by Zacks Equity Research
MiMedx Group, Inc. (MDXG) moved big last session, as its shares rose above 8% on the day.
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
by Zacks Equity Research
Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).
Roche Launches Antibody Test to Diagnose Prostate Cancer
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
Pacira Focuses on Lead Candidate Exparel's Label Expansion
by Zacks Equity Research
We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.
Ohr Pharmaceutical Provides Update on Squalamine Study
by Zacks Equity Research
Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).
OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal
by Zacks Equity Research
It was a bad day for OncoMed Pharmaceuticals, Inc. (OMED) as it suffered two setbacks.
Endo (ENDP) Reports Preliminary Results for First Quarter
by Zacks Equity Research
Endo International plc (ENDP) recently announced preliminary results for first-quarter 2017.
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
by Zacks Equity Research
Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.
Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint
by Zacks Equity Research
Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.
Ultragenyx's (RARE) XLH Drug Positive in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).
Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
Today's Strong Buy Stocks at New Highs
by David Bartosiak
Wild day in the markets and four strong buys at new highs
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst
by Zacks Equity Research
Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.
Roche Announces Positive Data on Lung Cancer Drug Alecensa
by Zacks Equity Research
Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.
Valeant (VRX) Faces Pricing Issues, Generic Threats Loom
by Zacks Equity Research
Shares of Valeant Pharmaceuticals International, Inc. (VRX) hit a 52-week low of $10.08 on Apr 4.
Agenus (AGEN) Sharpens Focus on Drug Development Programs
by Zacks Equity Research
We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
Amedisys (AMED) Poised on Strong Home Health, Risks Remain
by Zacks Equity Research
On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).
Galapagos Initiates 3 Phase II Studies for Filgotinib
by Zacks Equity Research
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.